Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Masatoshi Kudo(Kindai University), Yasuaki Arai(Tokyo National Hospital), Ann‐Lii Cheng(National Taiwan University), Hisashi Hidaka(Kitasato University), Hitoshi Arioka(Yokohama Rosai Hospital), Jeong Heo(National Cancer Center), Po‐Chin Liang(National Taiwan University Hospital), Namiki Izumi(Musashino Red Cross Hospital), Jae Hyung Park(Korea Advanced Institute of Science and Technology), Satoshi Morita(Kyoto University), I‐Shyan Sheen(Chang Gung University), Joong‐Won Park(National Cancer Center), Chang‐Fang Chiu(China Medical University), Youn Jae Lee(Inje University Busan Paik Hospital)
Cited by 200
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells.
|Journal of Biological Chemistry|1990|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k